#+TITLE: Methylmalonic Acidemia
#+AUTHOR: Matthew Henderson, PhD, FCACB
#+DATE: \today

:PROPERTIES:
#+DRAWERS: PROPERTIES
#+LaTeX_CLASS: beamer
#+LaTeX_CLASS_OPTIONS: [presentation, smaller]
#+BEAMER_THEME: Hannover
#+BEAMER_COLOR_THEME: whale
#+BEAMER_FRAME_LEVEL: 2
#+COLUMNS: %40ITEM %10BEAMER_env(Env) %9BEAMER_envargs(Env Args) %4BEAMER_col(Col) %10BEAMER_extra(Extra)
#+OPTIONS: H:2 toc:nil
#+PROPERTY: header-args:R :session *R*
#+PROPERTY: header-args :cache no
#+PROPERTY: header-args :tangle yes
#+STARTUP: beamer
#+STARTUP: overview
#+STARTUP: hidestars
#+STARTUP: indent
#  #+BEAMER_HEADER: \subtitle{Part 2: Organic Acidurias}
#+BEAMER_HEADER: \institute[NSO]{Newborn Screening Ontario | The University of Ottawa}
#+BEAMER_HEADER: \titlegraphic{\includegraphics[height=1cm,keepaspectratio]{../logos/NSO_logo.pdf}\includegraphics[height=1cm,keepaspectratio]{../logos/cheo-logo.png} \includegraphics[height=1cm,keepaspectratio]{../logos/UOlogoBW.eps}}
#+latex_header: \hypersetup{colorlinks,linkcolor=white,urlcolor=blue}
#+LaTeX_header: \usepackage{textpos}
#+LaTeX_header: \usepackage{textgreek}
#+LaTeX_header: \usepackage[version=4]{mhchem}
#+LaTeX_header: \usepackage{chemfig}
#+LaTeX_header: \usepackage{siunitx}
#+LaTeX_header: \usepackage{gensymb}
#+LaTex_HEADER: \usepackage[usenames,dvipsnames]{xcolor}
#+LaTeX_HEADER: \usepackage[T1]{fontenc}
#+LaTeX_HEADER: \usepackage{lmodern}
#+LaTeX_HEADER: \usepackage{verbatim}
#+LaTeX_HEADER: \usepackage{tikz}
#+LaTeX_HEADER: \usetikzlibrary{shapes.geometric,arrows,decorations.pathmorphing,backgrounds,positioning,fit,petri}
:END:
#+BEGIN_LaTeX
%\logo{\includegraphics[width=1cm,height=1cm,keepaspectratio]{../logos/NSO_logo_small.pdf}~%
%    \includegraphics[width=1cm,height=1cm,keepaspectratio]{../logos/UOlogoBW.eps}%
%}

\vspace{220pt}
\beamertemplatenavigationsymbolsempty
\setbeamertemplate{caption}[numbered]
\setbeamerfont{caption}{size=\tiny}
% \addtobeamertemplate{frametitle}{}{%
% \begin{textblock*}{100mm}(.85\textwidth,-1cm)
% \includegraphics[height=1cm,width=2cm]{cat}
% \end{textblock*}}

\tikzstyle{chemical} = [rectangle, rounded corners, text width=5em, minimum height=1em,text centered, draw=black, fill=none]
\tikzstyle{hardware} = [rectangle, rounded corners, text width=5em, minimum height=1em,text centered, draw=black, fill=gray!30]
\tikzstyle{ms} = [rectangle, rounded corners, text width=5em, minimum height=1em,text centered, draw=orange, fill=none]
\tikzstyle{msw} = [rectangle, rounded corners, text width=7em, minimum height=1em,text centered, draw=orange, fill=none]
\tikzstyle{label} = [rectangle,text width=8em, minimum height=1em, text centered, draw=none, fill=none]
\tikzstyle{hl} = [rectangle, rounded corners, text width=5em, minimum height=1em,text centered, draw=black, fill=red!30]
\tikzstyle{box} = [rectangle, rounded corners, text width=5em, minimum height=5em,text centered, draw=black, fill=none]
\tikzstyle{arrow} = [thick,->,>=stealth]
\tikzstyle{hl-arrow} = [ultra thick,->,>=stealth,draw=red]

#+END_LaTeX

* Introduction
** History
- First reported in 1967 by Oberholzer and Stokke
- Defect in methylmalonic mutase
  - catalyzes the isomerization of methylmalonyl-CoA to succinyl-CoA
- Requires adenosylcobalamin as a cofactor
  - derived from vitamin B_12
- Genetic heterogeneity was observed early
  - response to large doses of B_12
- B_12 responsive have defects in adenosylcobalamin synthesis
- B_12 unresponsive have defects in the apoenzyme methylmalonyl mutase
  - mut^- :: little activity
  - mut^0 :: no activity

** Methylmalonyl CoA Mutase
- Upon entry to the mitochondria, the 32 amino acid mitochondrial
  leader sequence at the N-terminus of the protein is cleaved, forming
  the fully processed monomer.
- The monomers associate into homodimers, and bind AdoCbl (one
  for each monomer active site) to form the active holoenzyme

#+BEGIN_SRC dot :file ./figures/mut.pdf :cmdline -Kdot -Tpdf
    digraph {
             // graph from left to right
             rankdir=LR;
             splines=true;
             node [shape=box];
             dmm [label="D-Methylmalonyl-CoA", fillcolor=steelblue3, style=filled]
             lmm [label="L-Methylmalonyl-CoA", fillcolor=steelblue3, style=filled]
             mma [label="Methylmalonic acid", fillcolor=red3, style=filled]    
             suc [label="Succinyl-CoA", fillcolor=steelblue3, style=filled]     
             s [label="Succinate", fillcolor=steelblue3, style=filled]     
             dmm -> lmm [label="Epimerase"]
             lmm -> suc [label="MCM + AdoCbl", color= red3]
             suc -> s [label="Ligase"] 
             dmm -> mma [style=dotted,dir=both]
             mma -> lmm [style=dotted,dir=both]
             }    
#+END_SRC

#+RESULTS:
[[file:./figures/mut.pdf]]

** Genetics
- autosomal recessive
- 1/50000
  - 1/2-2/3 have mutase apoenzyme defect 
- Methymalonyl pathway
- Cobalamin transport and metabolism
 
** Methylmalonyl CoA Pathway
- Methylmalonyl CoA Epimerase deficiency
- Methylmalonyl CoA mutase deficiency
  - mut^0, mut^{-}
  - >200 mutations in MUT locus identified
- Succinyl CoA ligase deficiency (SUCLG1, SUCLA1)

** Methylmalonyl-CoA  Pathway
\centering
#+ATTR_LATEX: :height 0.85\textheight
[[./figures/expanded_mma_path.png]]

** Cobalamin Transport and Metabolism
- Adenosyltransferase deficiency (Cbl B)
- Cbl A
- Homocystinuria w MMA (Cbl C, D)
- B_12 deficiency
  - Dietary (vegan)
  - Pernicious anemia
- Transcobalamin II deficiency
- B_12 transport from lysosome defect (Cbl F)

** Cobalamin Transport and Metabolism
[[./figures/cbl_path.png]]

** Methylmalonic Acid and Derivatives
\centering
#+BEGIN_LaTeX
\vspace{6em}
\chemname{\chemfig[][scale=.5]{OH-[1]([2]=O)-[7]([6]<)-[1]([2]=O)-[7]S-CoA}}{\tiny S-methylmalonyl-CoA}
\hspace{2em}
\chemname{\chemfig[][scale=.5]{OH-[1]([2]=O)-[7]([6]<:)-[1]([2]=O)-[7]S-CoA}}{\tiny R-methylmalonyl-CoA}
\hspace{2em}
\chemname{\chemfig[][scale=.5]{OH-[1]([2]=O)-[7]([6]-)-[1]([2]=O)-[7]OH}}{\tiny methylmalonic acid}
#+END_LaTeX

** Sources of Methylmalonic Acid
- AA catabolism
  - isoleucine
  - valine
  - threonine
  - methionine
- FA
  - \downarrow contribution to urine MMA

[[http://www.genome.jp/kegg-bin/show_pathway?scale=1.0&query=methylmalonyl-CoA&map=hsa00640&scale=&auto_image=&show_description=hide&multi_query=][propionate metabolism - KEGG]]

** Methylmalonyl-CoA

- inhibits PCC \to \uparrow PA
*** Hyperglycinemia
- inhibits synthesis of glycine cleaving enzyme.
- inhibits transport of malate, 2-ketoglutarate and isocitrate
*** CBC
- megaloblastosis in cblC defects
  - \downarrow methylcobalamin

*** Hyperammonemia
- PA inhibits carbamylphosphate synthetase
*** Ketosis
- PA inhibits mitochondrial oxidation of succinic acid and 2-ketoglutaric acid

* Laboratory Investigations
** NSO PA/MMA Screening Logic
*** Inital positive \lt 7 days
(C3/C2 \ge 0.21 AND C3 \ge 4.0)
OR
(C3/C2 \ge 0.23 AND C3 \ge 3.5)
*** Inital positive \gt 7 days
(C3/C2 \ge 0.21 AND C3 \ge 2.6)
OR
(C3/C2 \ge 0.23 AND C3 \ge 2.4)
  - Repeat overnight
  - No weekend reporting
*** Alert
C3/C2 \ge 0.3 AND C3 \ge 9.0
  - Repeat same day
  - Weekend reporting
*** Confirmation
 C3/C2 \ge 0.23 AND MCA \ge 0.5

** Clinical Chemistry
- Acidosis in acute episodes
  - accumulation of \beta-hydroxybutyrate and acetoacetate
  - Arterial pH as low as 6.9
  - Bicarb as low as 5 mEq/L
- \uparrow lactic acid
- Hypoglycemia
- Hyperammonemia
- Measure B12
 
** Biochemical Genetics
*** Plasma Amino Acids
- \pm glycine
- \uparrow glutamine when hyperammonemia
*** Plasma Acylcarnitines
- \uparrow propionyl carnitine (C3)
- \uparrow methylmalonyl carnitine (C4DC)

*** Urine Organic Acids
- methylmalonic acid
- 3-hydroxypropionic acid
- methylcitric acid
- tiglic acid / tiglyglycine
- Ketones
  - BHB
  - acetoacetate
- lactic acid

** Urine Organic Acids
[[./figures/mma_uoa.png]]

** Typical Urine Methylmalonic Acid Values

| Clinical Status                        | mmol/mol creatinine |
|----------------------------------------+---------------------|
| normal                                 |                 0-2 |
| Mut^0;presentation                     |          3000-13000 |
| Mut^0;steady state                     |            200-2000 |
| B_12 responsive;presentation           |                2000 |
| B_12 responsive;steady-state           |              90-300 |
| B_12 deficient infant                  |           4500-5700 |
| Transcobalamin II deficiency           |                 600 |
| Cobalamin C,D                          |                 270 |
| Atypical-normal mutase                 |                 200 |
| Succinyl CoA ligase                    |              80-120 |
| Methylmalonyl CoA epimerase deficiency |              30-300 |

* Clinical Findings
** Initial presentation
- Failure to thrive
  - \downarrow linear growth
- Skin lesions - candidasis
- Life-threatening illness early in life
  - ketonuria
    - acidosis
    - dehydration
  - vomiting
  - lethargy \to coma

** Acute Treatment
- aggressive intravenous hydration
  - efficient renal excretion of MMA
- Insulin and glucose \to anabolism
- Acute HGH

** Recurrent Symptoms
- ketotic episodes
- infection
- protein intolerance

** Long term 
- Variable developmental/cognitive outcomes
  - appears linked to incidence of illness
- severe hypotonia
- stroke
- hepatomegaly - normal LFTs
- \downarrown renal function
- pancreatitis
- candidasis
  - MMA inhibits maturation of hematopoietic cells and T cells

** Neurological Findings
- due to acute episodes
  - \downarrow cerebral perfusion
  - hypoglycemia
  - hyperammonemia
- more common in apo enzyme defect than Cbl 
- Successful treatment \to normal IQ
- 25 of 33 patients :
  - ataxia = lack of coordination
  - dystonia = muscle contraction
  - dyskinesia = involuntary movement
  - dsyarthria = speech
  - chorea = rythmic contractions
  - clonus = jerky movements
  - tremors

** Long-term Treatment
*** Diet
- Limit Val, Ile, Thr, Met
  - Monitor urine metabolites, plasma amino acids
  - Urine ketones (daily in infancy)
  - Monitor weight, nitrogen balance
- Avoid fasting
  - Catabolism
  - Propionate release from lipids

*** Supplementation
- test for B_{12} response
  - pharmacologic does of B_{12}
- carnitine
  - excretion of carnitine esters \to detoxification
  - Daily dose 60 to 100 mg/kg 
- ?alanine supplementation?

** Long-term Treatment
*** Medication
- Production of PA by intestinal bacteria
  - metronidazole
  - neomycin
- HGH \to anabolism

*** Transplantation
- liver transplantation does not stop progressive neurological symptoms
- liver & kidney may be considered


  
